News | February 18, 2022
Ligand posts strong 2021 performance
Ligand expects 2022 royalties of $55 million to $60 million, material sales of $40 million to $50 million, and contract revenue of $52 million to $62 million.
Ligand expects 2022 royalties of $55 million to $60 million, material sales of $40 million to $50 million, and contract revenue of $52 million to $62 million.
AptarGroup acquired Voluntis and 80% of Weihai Hengyu Medical Products in 2021.
Expected to open later this year, the facility will significantly increase distribution capacity to meet the growing demand for production materials by Ireland's biopharma industry
Prior to IHH, Anurag held senior leadership roles in Fortis Healthcare and Manipal Health Enterprises.
The transaction is expected to close in the first quarter of 2022
Clean Max Auriga Power is a special purpose vehicle engaged in the business of production, supply and distribution of solar and wind or other renewable energy generation plant
Investment in single-use endoscopes, digital solutions, and endoluminal therapies expected
Suchirayu owns a state-of-the-art multi-speciality hospital in Hubli with an operational capacity of 110 beds and a potential to scale up to 250 beds
Viyash has ten manufacturing facilities in India with a combined capacity of 2000 KL as well as one formulation facility in the US, and is now one of India’s leading mid-tier integrated API and formulation players
The company has operations in North America, Asia, and Europe,
Subscribe To Our Newsletter & Stay Updated
